5-Iodotubercidin

5-Iodotubercidin is an inhibitor of adenosine kinase (IC₅₀ = 0.026 µM).¹ It inhibits protein kinase A (PKA), phosphorylase kinase, casein kinase 1 (CK1), CK2, and PKC (IC₅₀s = 5-10, 5-10, 0.4, 10.9, and 0.4 µM, respectively).² 5-Iodotubercidin is also an inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA-dependent RNA polymerase (RdRp; EC₅₀ = 0.75 µM).³ It decreases fatty acid synthesis and increases fatty acid oxidation in isolated rat hepatocytes when used at a concentration of 20 µM.⁴ In vivo, 5-iodotubercidin reduces the number of seizures in a rat model of seizures induced by maximum electroshock (MES; ED₅₀ = 6 mg/kg).¹

WARNING This product is not for human or veterinary use.

1. Ugarkar, B.G., DaRe, J.M., Kopcho, J.J., et al. Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues. J. Med. Chem. 43(15), 2883-2893 (2000).

2. Massillon, D., Stalmans, W., van de Werve, G., et al. Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor. Biochem. J. 299, 123-128 (1994).

3. Zhao, J., Liu, Q., Yi, D., et al. 5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis. Antiviral Res. 198, 105254 (2022).

4. García-Villafranca, J., and Castro, J. Effects of 5-iodotubercidin on hepatic fatty acid metabolism mediated by the inhibition of acetyl-CoA carboxylase. Biochem. Pharmacol. 63, 1997-2000 (2002).